Radical radiotherapy for invasive bladder cancer: What dose and fractionation schedule to choose?
Journal Article
·
· International Journal of Radiation Oncology, Biology and Physics
- Department of Radiation Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (Netherlands)
- Department of Radiation Oncology, Free University Medical Center, Amsterdam (Netherlands)
Purpose: To establish the {alpha}/{beta} ratio of bladder cancer from different radiotherapy schedules reported in the literature and provide guidelines for the design of new treatment schemes. Methods and Materials: Ten external beam radiotherapy (EBRT) and five brachytherapy schedules were selected. The biologically effective dose (BED) of each schedule was calculated. Logistic modeling was used to describe the relationship between 3-year local control (LC3y) and BED. Results: The estimated {alpha}/{beta} ratio was 13 Gy (95% confidence interval [CI], 2.5-69 Gy) for EBRT and 24 Gy (95% CI, 1.3-460 Gy) for EBRT and brachytherapy combined. There is evidence for an overall dose-response relationship. After an increase in total dose of 10 Gy, the odds of LC3y increase by a factor of 1.44 (95% CI, 1.23-1.70) for EBRT and 1.47 (95% CI, 1.25-1.72) for the data sets of EBRT and brachytherapy combined. Conclusion: With the clinical data currently available, a reliable estimation of the {alpha}/{beta} ratio for bladder cancer is not feasible. It seems reasonable to use a conventional {alpha}/{beta} ratio of 10-15 Gy. Dose escalation could significantly increase local control. There is no evidence to support short overall treatment times or large fraction sizes in radiotherapy for bladder cancer.
- OSTI ID:
- 20793396
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Journal Name: International Journal of Radiation Oncology, Biology and Physics Journal Issue: 4 Vol. 64; ISSN IOBPD3; ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Use of Individual Fraction Size Data from 3756 Patients to Directly Determine the {alpha}/{beta} Ratio of Prostate Cancer
Prospective Multi-Institutional Study of Definitive Radiotherapy With High-Dose-Rate Intracavitary Brachytherapy in Patients With Nonbulky (<4-cm) Stage I and II Uterine Cervical Cancer (JAROG0401/JROSG04-2)
Treatment Results of PDR Brachytherapy Combined With External Beam Radiotherapy in 106 Patients With Intermediate- to High-Risk Prostate Cancer
Journal Article
·
Tue May 01 00:00:00 EDT 2007
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:20951611
Prospective Multi-Institutional Study of Definitive Radiotherapy With High-Dose-Rate Intracavitary Brachytherapy in Patients With Nonbulky (<4-cm) Stage I and II Uterine Cervical Cancer (JAROG0401/JROSG04-2)
Journal Article
·
Sat Dec 31 23:00:00 EST 2011
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:22055948
Treatment Results of PDR Brachytherapy Combined With External Beam Radiotherapy in 106 Patients With Intermediate- to High-Risk Prostate Cancer
Journal Article
·
Tue Mar 15 00:00:00 EDT 2011
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:21491642